Metropolitan Life Insurance Company (MetLife)’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-7,592
| Closed | -$115K | – | 1912 |
|
|
2024
Q1 | $115K | Sell |
7,592
-305
| -4% | -$4.86K | 0.01% | 972 |
|
|
2023
Q4 | $135K | Sell |
7,897
-450
| -5% | -$5.23K | 0.01% | 927 |
|
|
2023
Q3 | $69.8K | Buy |
8,347
+853
| +11% | +$11.9K | ﹤0.01% | 1207 |
|
|
2023
Q2 | $186K | Buy |
7,494
+286
| +4% | +$7.39K | 0.01% | 705 |
|
|
2023
Q1 | $108K | Sell |
7,208
-821
| -10% | -$12.5K | 0.01% | 959 |
|
|
2022
Q4 | $95K | Hold |
8,029
| – | – | ﹤0.01% | 1074 |
|
|
2022
Q3 | $47.5K | Buy |
8,029
+1,790
| +29% | +$11.7K | ﹤0.01% | 1490 |
|
|
2022
Q2 | $26.5K | Sell |
6,239
-2,387
| -28% | -$14.9K | ﹤0.01% | 1897 |
|
|
2022
Q1 | $82K | Sell |
8,626
-26,443
| -75% | -$306K | ﹤0.01% | 1330 |
|
|
2021
Q4 | $666K | Hold |
35,069
| – | – | 0.01% | 1235 |
|
|
2021
Q3 | $1.17M | Buy |
35,069
+433
| +1% | +$13.4K | 0.02% | 844 |
|
|
2021
Q2 | $1.34M | Buy |
34,636
+2,214
| +7% | +$86.9K | 0.02% | 784 |
|
|
2021
Q1 | $1.56M | Buy |
32,422
+250
| +0.8% | +$12K | 0.02% | 659 |
|
|
2020
Q4 | $1.67M | Hold |
32,172
| – | – | 0.03% | 567 |
|
|
2020
Q3 | $861K | Buy |
32,172
+2,485
| +8% | +$57.2K | 0.01% | 831 |
|
|
2020
Q2 | $578K | Buy |
29,687
+1,984
| +7% | +$32K | 0.01% | 1093 |
|
|
2020
Q1 | $273K | Buy |
27,703
+1,866
| +7% | +$23.6K | 0.01% | 1403 |
|
|
2019
Q4 | $287K | Sell |
25,837
-1,452
| -5% | -$11K | ﹤0.01% | 1665 |
|
|
2019
Q3 | $153K | Buy |
27,289
+5,738
| +27% | +$40K | ﹤0.01% | 2060 |
|
|
2019
Q2 | $186K | Buy |
21,551
+3,770
| +21% | +$28.5K | ﹤0.01% | 1932 |
|
|
2019
Q1 | $143K | Sell |
17,781
-2,193
| -11% | -$11.9K | ﹤0.01% | 2112 |
|
|
2018
Q4 | $81.9K | Hold |
19,974
| – | – | ﹤0.01% | 2394 |
|
|
2018
Q3 | $112K | Hold |
19,974
| – | – | ﹤0.01% | 2384 |
|
|
2018
Q2 | $263K | Buy |
19,974
+3,616
| +22% | +$49.7K | ﹤0.01% | 1761 |
|
|
2018
Q1 | $232K | Hold |
16,358
| – | – | ﹤0.01% | 1803 |
|
|
2017
Q4 | $134K | Sell |
16,358
-13,889
| -46% | -$121K | ﹤0.01% | 2144 |
|
|
2017
Q3 | $358K | Hold |
30,247
| – | – | ﹤0.01% | 1902 |
|
|
2017
Q2 | $304K | Hold |
30,247
| – | – | ﹤0.01% | 2058 |
|
|
2017
Q1 | $352K | Buy |
+30,247
| New | +$217K | ﹤0.01% | 1896 |
|
|
2016
Q4 | – | Sell |
-26,377
| Closed | -$204K | – | 2643 |
|
|
2016
Q3 | $204K | Buy |
26,377
+945
| +4% | +$6.08K | ﹤0.01% | 2328 |
|
|
2016
Q2 | $154K | Hold |
25,432
| – | – | ﹤0.01% | 2506 |
|
|
2016
Q1 | $217K | Hold |
25,432
| – | – | ﹤0.01% | 2124 |
|
|
2015
Q4 | $303K | Hold |
25,432
| – | – | ﹤0.01% | 1959 |
|
|
2015
Q3 | $256K | Hold |
25,432
| – | – | ﹤0.01% | 2108 |
|
|
2015
Q2 | $422K | Buy |
25,432
+5,984
| +31% | +$94.8K | ﹤0.01% | 1862 |
|
|
2015
Q1 | $301K | Hold |
19,448
| – | – | ﹤0.01% | 1843 |
|
|
2014
Q4 | $308K | Hold |
19,448
| – | – | ﹤0.01% | 2109 |
|
|
2014
Q3 | $208K | Hold |
19,448
| – | – | ﹤0.01% | 2339 |
|
|
2014
Q2 | $183K | Buy |
+19,448
| New | +$124K | ﹤0.01% | 2571 |
|
Other funds holding TGTX
SCM
DTC
OM
Metropolitan Life Insurance Company (MetLife)'s TGTX Position: Q2 2024 in Review
Metropolitan Life Insurance Company (MetLife) sold out of TG Therapeutics (TGTX) in Q2 2024, closing a stake of 7,592 shares — an estimated $115K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in TGTX in Q2 2014 and held it in 39 quarters. The position peaked at $1.67M in Q4 2020. 259 funds tracked by Wall St. Rank hold TGTX as of Q2 2024.
- Metropolitan Life Insurance Company (MetLife) reported no remaining TG Therapeutics position as of Q2 2024 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 7,592 TG Therapeutics shares in Q2 2024, an estimated $115K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in TG Therapeutics in Q2 2014 and held it in 39 quarters.
- Metropolitan Life Insurance Company (MetLife)'s TG Therapeutics position peaked at $1.67M in Q4 2020.
- 259 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2024.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.